Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies

导出原文传递

翻译打印收藏纠错

作者： Pepper, Andrea G. S. ^[1] ; Zucchetto, Antonella ^[2] ; Norris, Kevin ^[3] ; Tissino, Erika ^[4] ; Polesel, Jerry ^[5] ; Soe, Zarni ^[6] ; Allsup, David ^[7] ; Hockaday, Anna ^[8] ; Ow, Pei Loo ^[9] ; Hillmen, Peter ; Rawstron, Andrew ; Catovsky, Daniel ; Bulian, Pietro ; Bomben, Riccardo ; Baird, Duncan M. ; Fegan, Christopher D. ; Gattei, Valter ; Pepper, Chris

作者单位： Sch Med,Cardiff Univ ^[1] Brighton & Sussex Med Sch,Univ Sussex ^[2] Leeds Teaching Hosp Trust ^[3] Hull York Med Sch,Univ Hull ^[4] Inst Canc Res ^[5] Leeds Inst Clin Trials Res,Univ Leeds ^[6] Clin & Expt Oncohematol Unit,Ctr Riferimento Oncol Aviano CRO IRCCS ^[7] Leeds Inst Med Res St Jamess,Univ Leeds ^[8] Unit Canc Epidmiol,Ctr Riferimento Oncol Aviano CRO IRCCS ^[9]

关键词 CHRONIC LYMPHOCYTIC-LEUKEMIA CYCLOPHOSPHAMIDE FLUDARABINE PREDICTION RITUXIMAB TRIAL

发布时间 2022-03-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交